Hayakawa Yoichi, Tomikawa Taijiro, Shin-ya Kazuo, Arao Nakako, Nagai Koji, Suzuki Ken-ichi
Institute of Molecular and Cellular Biosciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0032, Japan.
J Antibiot (Tokyo). 2003 Nov;56(11):899-904. doi: 10.7164/antibiotics.56.899.
Our screening for antitumor antibiotics against transformed cells resulted in the isolation of a new active metabolite, oximidine III, from Pseudomonas sp. QN05727. This substance selectively inhibited the growth of rat 3Y1 fibroblasts transformed with various oncogenes. In ras- or src-transformed cells, oximidine III arrested the cell cycle at G1 phase and increased the expression of p21WAF1.